WSL
PHAT icon

Western Standard LLC’s Phathom Pharmaceuticals PHAT Stock Holding History

Western Standard LLC’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-109,055
Closed -$920K – 33
2022
Q2 		$920K Buy
+109,055
New +$1.12M 0.7% 32

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Western Standard LLC's PHAT Position: Q3 2022 in Review

Western Standard LLC sold out of Phathom Pharmaceuticals (PHAT) in Q3 2022, closing a stake of 109,055 shares — an estimated $920K sold.

Western Standard LLC first reported a position in PHAT in Q2 2022 and held it in 1 quarter. The position peaked at $920K in Q2 2022. 94 funds tracked by Wall St. Rank hold PHAT as of Q3 2022.

  • Western Standard LLC reported no remaining Phathom Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Western Standard LLC sold 109,055 Phathom Pharmaceuticals shares in Q3 2022, an estimated $920K.
  • Western Standard LLC first reported a position in Phathom Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Western Standard LLC's Phathom Pharmaceuticals position peaked at $920K in Q2 2022.
  • 94 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2022.

Based on Western Standard LLC's 13F filing for Q3 2022, filed 14 Nov 2022.